Tamoxifen stimulates phospholipase D activity by an estrogen receptor‐independent mechanism

@article{Kiss1994TamoxifenSP,
  title={Tamoxifen stimulates phospholipase D activity by an estrogen receptor‐independent mechanism},
  author={Z. Kiss},
  journal={FEBS Letters},
  year={1994},
  volume={355}
}
  • Z. Kiss
  • Published 1994
  • Chemistry, Medicine
  • FEBS Letters
The effects of tamoxifen (TAM), a widely used agent in the treatment of breast cancer, were examined on phospholipase D (PLD)‐mediated phospholipid hydrolysis. In drug‐sensitive MCF‐7 human breast carcinoma cells TAM, similar to several well‐established activators of PLD, had no effect on phospholipid hydrolysis. In an estrogen receptor‐deficient multidrug‐resistant subline of MCF‐7 cells, TAM preferentially stimulated the hydrolysis of phosphatidylethanolamine; two‐fold stimulation required 2… Expand
Tamoxifen activates cellular phopholipase C and D and elicits protein kinase C translocation
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen.
Concentration dependency of modulatory effect of amlodipine on P‐glycoprotein efflux activity of doxorubicin — a comparison with tamoxifen
Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells
...
1
2
...

References

SHOWING 1-10 OF 42 REFERENCES
Inhibition of protein kinase C by tamoxifen.
Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells.
Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.
  • H. Lam
  • Chemistry, Medicine
  • Biochemical and biophysical research communications
  • 1984
...
1
2
3
4
5
...